iPSC-Derived Cell Therapies Summit

Memo

Innovate The Next Generation of Safe, Scalable and Cost-Effective iPSC-Derived Therapies The explosion of excitement and investment in the iPSC field has ushered in a new era of cell therapy, with these cells establishing it’s place as the optimal starting material for cell therapies targeting cancer, autoimmune, cardiac disease and much more. The iPSC-Derived Cell Therapies Summit is your dedicated forum exclusively focused on the common challenges across disease indications which are limiting the clinical translation of iPSC-based approaches for cell therapy, including safety concerns with differentiation protocols, lack of regulatory guidance, and licensing issues. Get caught up to speed on this dynamic industry with expertise shared from the likes of Shoreline Biosciences, Kite Pharma, HeartSeed, and Exacis, to understand the broad applicability of iPSCs, advances in novel gene engineering approaches, and translational lessons learned to advance your pipeline to clinical success. Leave this meeting with the knowledge and connections to landscape the clinical progression, outline GMP compliant processes for scale up, and share strategies to ensure consistency in starting material. This is your opportunity to collaborate with 80+ iPSC senior level experts from biopharma and academia, and be at the forefront of the future of cell therapy by joining the mission to develop safe, scalable and cost-effective iPSC-derived therapies. Running digitally December 7-9, 2021. Group discounts and early booking rates are available. Please visit the website for full pricing information. Date and Time: On Tuesday December 07, 2021 at 9:00 am (ends Thursday December 09, 2021 at 5:00 pm) Prices: Conference + 2 Workshops (Industry Pricing): USD 2897.00,Conference + 1 Workshop (Industry Pricing): USD 2498.00,Conference Only (Industry Pricing): USD 2099.00,Conference + 2 Workshops (Academic Pricing): USD 2497.00,Conference + 1 Workshop (Academic Pricing): USD 2198.00,Conference Only (Academic Pricing): USD 1899.00,Conference + 2 Workshops (Solution Provider Pricing): USD 3597.00,Conference + 1 Workshop (Solution Provider Pricing): USD 3098.00,Conference + 1 Workshop (Solution Provider Pricing): USD 2599.00 URLs: Tickets: https://go.evvnt.com/853667-1?pid=5569 Brochure: https://go.evvnt.com/853667-3?pid=5569 Speakers: Helen Tayton-Martin, CBO, Adaptimmune, Jo Brewer, Head of Allogenic Research, Adaptimmune, Andres Bratt-Leal, Co-Founder, Aspen Neuroscience, Kristen Fantetti, Director, Associate Director Regulatory Affairs, BlueRock Therapeutics, Richard Boyd, CSO, Cartherics PL, Killian Kelly, COO, Cynata Therapeutics, Stanley Frankel, CMO, Cytovia Therapeutics, Wei Lei, CSO, Cytovia Therapeutics, Gregory Fiore, President and CEO, Exacis Biotherapeutics, Keiichi Fukuda, CEO, Heartseed, Kimberly Schluns, Senior Director Research, Kite Pharma, Kapil Bharti, Senior Investigator, NIH, David Main, CEO, Notch Therapeutics, Emily Titus, Vice President, Process Sciences, Notch Therapeutics, Jeanne Loring, Professor, Scripps Research, Dan Kaufman, CSO and Professor, Shoreline Biosciences; UC- San Diego, Geoff Hamilton, Co-Founder and CEO, Stemson Therapeutics, Douglas Falk, CEO, Vita Therapeutics, Peter Anderson, CSO, Vita Therapeutics, Teisha Rowland, Principal Scientist, Umoja Biopharma